Tyvaso Inhalation Solution for Pulmonary Hypertension Associated with Interstitial Lung Disease

Dr. Steven Nathan, MD, Medical Director, Advanced Lung Disease and Lung Transplant Programs at Inova Fairfax Hospital discusses the recent FDA approval (April 2021) of Tyvaso Inhalation Solution for the treatment of patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD) to improve exercise ability.  The approval is based on data from the INCREASE clinical trial, the largest and most comprehensive completed study of adult patients with PH-ILD.  He provides perspective on how physicians can treat patients in need with this first and only approved treatment in the PH-ILD space.

Steven D. Nathan, MD, FCCP, is director of the Advanced Lung Disease Program and director of the Lung Transplant Program at Inova Fairfax Hospital. He also is professor of medicine at Virginia Commonwealth University Inova Campus. Dr. Nathan is board certified in pulmonary diseases, critical care medicine and internal medicine.

The author of more than 380 publications, Dr. Nathan has written original research manuscripts, abstracts, reviews, book chapters and a book on idiopathic pulmonary fibrosis (IPF), which he coedited. Dr. Nathan is a reviewer for multiple journals and is on the editorial board for the journal, Thorax. He has served on multiple committees, including the U.S. Food and Drug Administration advisory boards as well as steering committees for clinical trials in IPF and pulmonary hypertension, where he has also served as chair. He is also chairperson of Pilot for IPF, an international educational initiative for pulmonary fibrosis.

Dr. Nathan is a member of several professional medical associations, including the American Thoracic Society, the American College of Chest Physicians, and the International Society for Heart and Lung Transplantation. He has delivered talks and been chairperson of numerous sessions at many national and international conferences.